Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of California, San Francisco
University of Oklahoma
Exelixis
Genmab
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Myeloid Therapeutics
Genentech, Inc.